Dysadherin expression promotes the motility and survival of human breast cancer cells by AKT activation

Cancer Science

Volumn 103, Issue 7, 2012, Pages 1280-1289

  Lee, Yoo Kyung ^a   Lee, Su Youn ^a   Park, Jeong Ran ^a   Kim, Ran Ju ^a   Kim, Soo Rim ^a   Roh, Kyung Jin ^a   Nam, Jeong Seok ^a  

^a Gachon University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; DYSADHERIN; PROTEIN KINASE B; TRICIRIBINE;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL MOTILITY; CELL SURVIVAL; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; MCF-7 CELLS; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; PACLITAXEL; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBONUCLEOSIDES; RNA INTERFERENCE;

EID: 84863303341     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02302.x     Document Type: Article

References (36)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Moody SE, Perez D, Pan TC et al. The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell 2005; 8: 197-209.
3. Ino Y, Gotoh M, Sakamoto M, Tsukagoshi K, Hirohashi S. Dysadherin, a cancer-associated cell membrane glycoprotein, down-regulates E-cadherin and promotes metastasis. Proc Natl Acad Sci USA 2002; 99: 365-70.
4. Shimamura T, Yasuda J, Ino Y et al. Dysadherin expression facilitates cell motility and metastatic potential of human pancreatic cancer cells. Cancer Res 2004; 64: 6989-95.
5. Nam JS, Kang MJ, Suchar AM et al. Chemokine (C-C motif) ligand 2 mediates the prometastatic effect of dysadherin in human breast cancer cells. Cancer Res 2006; 66: 7176-84.
6. Nam JS, Hirohashi S, Wakefield LM. Dysadherin: a new player in cancer progression. Cancer Lett 2007; 255: 161-9.
7. Park JR, Kim RJ, Lee YK et al. Dysadherin can enhance tumorigenesis by conferring properties of stem-like cells to hepatocellular carcinoma cells. J Hepatol 2011; 54: 122-31.
8. Dolcet X, Llobet D, Pallares J, Matias-Guiu X. NF-kB in development and progression of human cancer. Virchows Arch 2005; 446: 475-82.
9. Prasad S, Ravindran J, Aggarwal BB. NF-kappaB and cancer: how intimate is this relationship. Mol Cell Biochem 2010; 336: 25-37.
10. LoPiccolo J, Granville CA, Gills JJ, Dennis PA. Targeting Akt in cancer therapy. Anticancer Drugs 2007; 18: 861-74.
11. Liu W, Bagaitkar J, Watabe K. Roles of AKT signal in breast cancer. Front Biosci 2007; 12: 4011-9.
12. Staal SP. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci U S A 1987; 84: 5034-7.
13. Sun M, Wang G, Paciga JE et al. AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 2001; 159: 431-7.
14. Perez-Tenorio G, Stal O. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 2002; 86: 540-5.
15. Qiao M, Sheng S, Pardee AB. Metastasis and AKT activation. Cell Cycle 2008; 7: 2991-6.
16. Chin YR, Toker A. Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer. Cell Signal 2009; 21: 470-6.
17. Nam JS, Suchar AM, Kang MJ et al. Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of transforming growth factor beta in a mouse model of breast cancer. Cancer Res 2006; 66: 6327-35.
18. Kim RJ, Kim SR, Roh KJ et al. Ras activation contributes to the maintenance and expansion of Sca-1pos cells in a mouse model of breast cancer. Cancer Lett 2010; 287: 172-81.
19. Shimamura T, Sakamoto M, Ino Y et al. Dysadherin overexpression in pancreatic ductal adenocarcinoma reflects tumor aggressiveness: relationship to e-cadherin expression. J Clin Oncol 2003; 21: 659-67.
20. Nam JS, Ino Y, Kanai Y, Sakamoto M, Hirohashi S. 5-aza-2′-deoxycytidine restores the E-cadherin system in E-cadherin-silenced cancer cells and reduces cancer metastasis. Clin Exp Metastasis 2004; 21: 49-56.
21. Wang X, Nagase H, Watanabe T et al. Inhibition of MMP-9 transcription and suppression of tumor metastasis by pyrrole-imidazole polyamide. Cancer Sci 2010; 101: 759-66.
22. Yamazaki D, Kurisu S, Takenawa T. Regulation of cancer cell motility through actin reorganization. Cancer Sci 2005; 96: 379-86.
23. Kang Y, Massague J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 2004; 118: 277-9.
24. Nakayama S, Torikoshi Y, Takahashi T et al. Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells. Breast Cancer Res 2009; 11: R12.
25. Jimenez C, Hernandez C, Pimentel B, Carrera AC. The p85 regulatory subunit controls sequential activation of phosphoinositide 3-kinase by Tyr kinases and Ras. J Biol Chem 2002; 277: 41556-62.
26. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2: 442-54.
27. Graudens E, Boulanger V, Mollard C et al. Deciphering cellular states of innate tumor drug responses. Genome Biol 2006; 7: R19.
28. Bentires-Alj M, Barbu V, Fillet M et al. NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 2003; 22: 90-7.
29. McCubrey JA, Steelman LS, Abrams SL et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 2006; 46: 249-79.
30. Eckert LB, Repasky GA, Ulku AS et al. Involvement of Ras activation in human breast cancer cell signaling, invasion, and anoikis. Cancer Res 2004; 64: 4585-92.
31. Makiguchi Y, Hinoda Y, Imai K. Effect of MUC1 mucin, an anti-adhesion molecule, on tumor cell growth. Jpn J Cancer Res 1996; 87: 505-11.
32. Tsuiji H, Takasaki S, Sakamoto M, Irimura T, Hirohashi S. Aberrant O-glycosylation inhibits stable expression of dysadherin, a carcinoma-associated antigen, and facilitates cell-cell adhesion. Glycobiology 2003; 13: 521-7.
33. Kometiani P, Li J, Gnudi L, Kahn BB, Askari A, Xie Z. Multiple signal transduction pathways link Na+/K + -ATPase to growth-related genes in cardiac myocytes. The roles of Ras and mitogen-activated protein kinases. J Biol Chem 1998; 273: 15249-56.
34. Mohammadi K, Kometiani P, Xie Z, Askari A. Role of protein kinase C in the signal pathways that link Na+/K + -ATPase to ERK1/2. J Biol Chem 2001; 276: 42050-6.
35. Barwe SP, Anilkumar G, Moon SY et al. Novel role for Na, K-ATPase in phosphatidylinositol 3-kinase signaling and suppression of cell motility. Mol Biol Cell 2005; 16: 1082-94.
36. Tsai EM, Wang SC, Lee JN, Hung MC. Akt activation by estrogen in estrogen receptor-negative breast cancer cells. Cancer Res 2001; 61: 8390-2.